Jennifer Moreno VA San Diego Healthcare System, San Diego, California; Division of Gastroenterology, Department of Internal Medicine, University of California San Diego, La Jolla, California; Division of Preventative Medicine, Department of Family Medicine and Public Health, UC San Diego Moores Cancer Center, La Jolla, California.
Veterans Medical Research Foundation, San Diego, California.
Clin Gastroenterol Hepatol. 2023 Jul;21(7):1924-1936.e9. doi: 10.1016/j.cgh.2022.10.003. Epub 2022 Oct 19.
Postpolypectomy risk stratification for subsequent metachronous advanced neoplasia (MAN) is imprecise and does not account for colonoscopist adenoma detection rate (ADR). Our aim was to assess association of ADR with MAN and create a prediction model for postpolypectomy risk stratification incorporating ADR and other factors.
We conducted a retrospective cohort study of individuals with baseline polypectomy and subsequent surveillance colonoscopy from 2004 to 2016 within the U.S. Department of Veterans Affairs (VA). Clinical factors, polyp findings, and baseline colonoscopist ADR were considered for the model. Model performance (sensitivity, specificity, and area under the curve) for identifying individuals with MAN was compared with 2020 U.S. Multi-Society Task Force on Colorectal Cancer (USMSTF) surveillance recommendations.
A total of 30,897 individuals were randomly assigned 2:1 into independent model training and validation sets. Increasing age, male sex, diabetes, current smoking, adenoma number, polyp location, adenoma ≥10 mm or with tubulovillous/villous features, and decreasing colonoscopist ADR were independently associated with MAN. A range of 1.48- to 1.66-fold increased risk for MAN was observed for ADR in the lowest 3 quintiles (ADR <19.7%-39.3%) vs the highest quintile (ADR >47.0%). When the final model selected based on the training set was applied to the validation set, improved sensitivity and specificity over 2020 USMSTF risk stratification were achieved (P = .001), with an area under the curve of 0.62 (95% confidence interval, 0.60-0.64).
Colonoscopist ADR is associated with MAN. Combining clinical factors and ADR for risk stratification has potential to improve postpolypectomy risk stratification. Improving ADR is likely to improve postpolypectomy outcomes.
对随后出现的异时性高级别腺瘤(MAN)的息肉切除后风险分层并不精确,且未考虑结肠镜医师腺瘤检出率(ADR)。我们的目的是评估 ADR 与 MAN 的关联,并创建一个包含 ADR 及其他因素的息肉切除后风险分层预测模型。
我们在美国退伍军人事务部(VA)内进行了一项回顾性队列研究,纳入了 2004 年至 2016 年期间基线行息肉切除术且随后进行结肠镜检查监测的个体。模型中考虑了临床因素、息肉发现和基线结肠镜医师 ADR。比较了该模型对 MAN 个体的识别效能(敏感性、特异性和曲线下面积)与 2020 年美国多学会工作组关于结直肠癌监测的建议。
共 30897 名个体被随机分配为模型训练集和验证集,比例为 2:1。年龄增长、男性、糖尿病、当前吸烟、腺瘤数量、息肉位置、腺瘤≥10mm 或具有管状绒毛/绒毛状特征、以及结肠镜医师 ADR 降低与 MAN 独立相关。ADR 处于最低 3 个五分位数(ADR<19.7%-39.3%)的个体,与 ADR 处于最高五分位数(ADR>47.0%)的个体相比,发生 MAN 的风险增加 1.48-1.66 倍。当应用于验证集时,基于训练集选择的最终模型可提高 2020 年美国多学会工作组风险分层的敏感性和特异性(P=0.001),曲线下面积为 0.62(95%置信区间,0.60-0.64)。
结肠镜医师 ADR 与 MAN 相关。将临床因素与 ADR 相结合进行风险分层,有可能改善息肉切除后的风险分层。提高 ADR 可能会改善息肉切除后的结果。